Full text is available at the source.
Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine
From Aging Biology to Targeted Treatments and Personalized Medicine for Healthy Aging
AI simplified
Abstract
The 40-month study on metformin in cynomolgus monkeys indicated a deceleration of plasma proteomic biological age by 6.41 years.
- Geroscience investigates the link between aging biology and age-related diseases, identifying aging as a key modifiable risk factor.
- Twelve hallmarks of aging processes and associated molecular pathways have been categorized to facilitate understanding of aging mechanisms.
- The WHO has recognized Ageing-Associated Decline in Intrinsic Capacity as an ICD-11 code, and the FDA has approved the TAME trial to evaluate aging interventions.
- Advancements in aging biomarkers range from DNA methylation clocks to organ-specific plasma proteomic signatures, enhancing disease prediction accuracy.
- Emerging gerotherapeutics include metformin, senolytics, and GLP-1 receptor agonists, each targeting different aspects of aging and age-related conditions.
- Multidomain lifestyle programs have shown effectiveness in improving intrinsic capacity in older adults through randomized trials.
AI simplified